Major depressive disorder affects more than 280 million people worldwide, and for roughly one in three of them, standard antidepressant medications do not produce adequate relief (National Institutes of Health). That gap has a clinical name: treatment-resistant depression. Understanding what that term actually means, and what distinguishes it from depression that simply has not yet been adequately treated, matters enormously for the patients living with it.
The Clinical Definition
Treatment-resistant depression has a specific meaning that gets lost when the term is used loosely. Clinically, it refers to a major depressive episode that has not responded adequately to at least two antidepressant medications at therapeutic doses, taken for a sufficient duration, typically six to eight weeks each (National Institutes of Health). This standard exists because both criteria matter: the right dose and the right duration. Depression that has not responded to a medication prescribed below its therapeutic threshold, or discontinued before it had a chance to work, does not meet the clinical definition of treatment-resistant.
This distinction matters practically. Some patients arrive at a TRD designation having gone through medications that were never fully trialed. For others, the history is unambiguous: multiple adequate trials at therapeutic doses, completed for the recommended duration, with insufficient response. The evaluation process at DreamWork examines this history carefully before any treatment decision is made, because the clinical picture shapes what the right next step actually is.
What Adequate Response Means
The threshold for “adequate response” is itself a subject of clinical discussion, but in practice it refers to meaningful reduction in symptom severity, not simply the absence of side effects or the ability to tolerate the medication. Depression is assessed across multiple domains: mood, energy, sleep, appetite, concentration, interest in daily activities, and sense of self (Mayo Clinic). A response that improves one domain while leaving others unchanged may represent partial response rather than adequate response, and partial response is a pattern that warrants attention and a different approach.
Partial responders represent a significant portion of the treatment-resistant population. These are patients who are better than they were before medication, but not well. They function, but not at the level they did before the depressive episode. For these patients, a common clinical error is to accept partial improvement as success and maintain the same treatment indefinitely, when what the partial response actually signals is that the current approach is not reaching the full neurobiology of the condition.
Why Some Depression Resists Standard Medication
Standard antidepressants, primarily SSRIs and SNRIs, work by increasing the availability of serotonin and norepinephrine in the brain. These medications help a significant portion of patients with major depressive disorder. The patients they do not help often have depression driven in part by systems that these medications do not directly address.
Research has established the glutamate system, the brain’s primary excitatory neurotransmitter network, as a key pathway in many cases of treatment-resistant depression (National Institute of Mental Health, 2024). Ketamine and esketamine produce antidepressant effects through glutamate pathways rather than monoamine ones, which is why they can work for patients whose depression has not responded to medications that target serotonin or norepinephrine.
Genetic factors also play a role. Variations in how individuals metabolize certain drug classes can render standard doses ineffective or poorly tolerated before they have a chance to demonstrate whether they would work at therapeutic levels. Underlying medical conditions, including thyroid dysfunction, chronic inflammation, and sleep disorders, can independently sustain depressive symptoms regardless of whether antidepressant treatment is optimized. A thorough TRD evaluation looks at all of these factors rather than assuming that the diagnosis itself is the only explanation.
How TRD Is Different From Difficult Depression
Not all depression that is hard to treat is treatment-resistant in the clinical sense. Depression in the context of active trauma, ongoing substance use, untreated co-occurring conditions, or inadequately trialed medications may be difficult and persistent without meeting TRD criteria. The distinction matters because the next clinical steps are different.
For a patient who has never had an adequate medication trial, the answer may be a different medication at the right dose with proper monitoring. For a patient with a genuine TRD history, the answer is likely a different class of treatment entirely. Treating the former the same as the latter can mean cycling through medications for years without a clear reason, while the patient continues to suffer. Treating the latter the same as the former can mean offering advanced treatments before simpler options have been genuinely exhausted. The evaluation is the tool that separates these two clinical pictures.
What the Evaluation Looks Like at DreamWork
Before recommending any treatment for suspected treatment-resistant depression, our team conducts a thorough psychiatric evaluation. This means reviewing your full medication history, including what you took, at what doses, for how long, and what your response was. It means screening for co-occurring conditions, medical factors, and patterns in your history that may explain inadequate responses. And it means being honest with you about what we find, including whether your prior trials actually met the clinical threshold for treatment-resistance, or whether there are options that have not yet been given a genuine trial.
Dr. Jahi Anderson, our board-certified psychiatrist and medical director, has more than fifteen years of clinical experience specifically in mood disorders, including treatment-resistant presentations. He leads every TRD evaluation at DreamWork. Our team does not default to advanced treatments before the evaluation is complete, and we do not avoid them when the history supports them.
Treatment Options for TRD at DreamWork
For patients who meet clinical criteria for treatment-resistant depression, DreamWork offers several evidence-based options at our Frisco and Sherman, TX locations.
SPRAVATO® is the first FDA-approved medication of its kind for TRD, delivered as a nasal spray in a monitored clinical setting. It works through the glutamate system and is covered by most major insurance plans when clinical criteria are met.
TMS therapy uses focused magnetic pulses to directly stimulate neural circuits in the brain associated with mood regulation, without medication or sedation. The FDA cleared TMS for major depressive disorder in 2008. At DreamWork, we use the NeuroStar Advanced TMS system.
IV ketamine therapy is also available for patients with TRD and co-occurring conditions including PTSD and chronic pain. Candidates undergo thorough screening before treatment is recommended.
Structured medication management through our psychiatry team may identify untried approaches, including augmentation strategies and, where appropriate, pharmacogenomic testing to assess whether metabolic factors have contributed to prior medication failures.
Results vary by individual across all of these options. The right treatment depends on the specific clinical picture that the evaluation reveals.
Insurance and Getting Started
We accept all major insurance plans at DreamWork, including Medicare, Blue Cross Blue Shield, Aetna, UnitedHealthcare, Cigna, United Medical Resources, Magellan, and TriWest Healthcare Alliance. SPRAVATO® and TMS are covered by many major plans when clinical criteria are met. Our team handles prior authorization for both before treatment begins. No referral is required to schedule an evaluation.
Call us at 214-592-8159 or reach out through our website to schedule a consultation at our Frisco or Sherman, TX location.
Frequently Asked Questions
How do I know if my depression is treatment-resistant?
The clinical threshold is two or more antidepressant trials at therapeutic doses for adequate duration without sufficient response. If you are unsure whether your prior treatment history meets that standard, a psychiatric evaluation will clarify it. Some patients who believe they have treatment-resistant depression have not completed fully adequate trials. Others clearly meet the criteria. The evaluation is the right starting point either way.
Is treatment-resistant depression permanent?
No. Treatment-resistant depression is a clinical description of how a patient has responded to specific treatments, not a prognosis for the rest of their life. The range of available options for TRD has expanded considerably in the past decade, and most patients who come to us have not tried all of them. Results vary by individual.
What is the difference between treatment-resistant depression and bipolar disorder?
Bipolar disorder involves alternating periods of depression and elevated mood, which can make standard antidepressants less effective and, in some cases, destabilizing. A thorough psychiatric evaluation includes screening for bipolar spectrum features because the treatment strategy for bipolar depression is different from the strategy for unipolar TRD. Misdiagnosis in this area is one of the reasons some patients cycle through antidepressants without improvement.
How is SPRAVATO® different from other antidepressants?
SPRAVATO® works through the glutamate system in the brain rather than the serotonin and norepinephrine systems targeted by SSRIs and SNRIs. It is administered as a nasal spray in a monitored clinical setting and is FDA-approved specifically for treatment-resistant depression. It is the first medication of its class to receive this approval, and it can be used as a standalone treatment without requiring combination with an oral antidepressant.
What happens if TMS and SPRAVATO® don’t work either?
The honest answer is that we do not guarantee outcomes for any treatment, and no ethical provider can. What we can tell you is that the range of options for treatment-resistant depression extends beyond the two most visible ones, and that a patient who has not responded to SPRAVATO® or TMS has not exhausted every available path. Our evaluation process is designed to identify what has not yet been tried and whether it is clinically supported for your specific situation. Discuss your full history with our team.
Key Takeaways
- Treatment-resistant depression is clinically defined as a major depressive episode that has not responded adequately to at least two antidepressants at therapeutic doses for adequate duration. It is a clinical designation, not a permanent condition.
- Partial response, where symptoms improve but do not resolve, is a distinct pattern that warrants a different treatment approach rather than continued maintenance of the same regimen.
- TRD often involves neurological pathways, particularly the glutamate system, that standard serotonin and norepinephrine-targeted medications do not directly address.
- At DreamWork, evidence-based options for TRD include SPRAVATO®, TMS therapy, IV ketamine, and comprehensive medication management and psychiatry. Every treatment recommendation is preceded by a thorough evaluation.
- Results vary by individual. DreamWork accepts all major insurance plans, and SPRAVATO® and TMS are covered by many plans when clinical criteria are met.
What the Diagnosis Tells Us
A history of inadequate response to antidepressants is specific clinical information. At DreamWork Wellness Center, our team in Frisco and Sherman, TX uses that history as the starting point for every TRD evaluation, asking what it tells us about the neurobiology of your depression and what that means for the right next step. Call us at 214-592-8159 or reach out through our website to schedule a consultation. Discuss your full treatment history with our team, and we will give you a direct answer about what may help.
References
National Institutes of Health. Antidepressant Efficacy in Treatment-Resistant Depression. https://pubmed.ncbi.nlm.nih.gov/23982301/
Mayo Clinic. Depression: Symptoms and Causes. https://www.mayoclinic.org/diseases-conditions/depression/symptoms-causes/syc-20356007
National Institute of Mental Health. New Hope for Rapid-Acting Depression Treatment (2024). https://www.nimh.nih.gov/news/science-updates/2024/new-hope-for-rapid-acting-depression-treatment
Medical Disclaimer
The information in this blog is for educational purposes only and does not constitute medical advice. Treatment for depression, including advanced options such as SPRAVATO®, TMS therapy, and IV ketamine, should only be pursued under the supervision of a licensed psychiatric provider familiar with your full medical and psychiatric history. Individual results vary. If you are experiencing a mental health crisis or thoughts of self-harm, please call or text 988 to reach the Suicide and Crisis Lifeline or go to your nearest emergency room.
